Loading clinical trials...
Loading clinical trials...
The results of the study suggest that an early change in CgA levels might serve as a prognostic factor in NET patients treated with PRRT.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Start Date
October 1, 2016
Primary Completion Date
September 30, 2023
Completion Date
September 30, 2023
Last Updated
December 27, 2023
38
ACTUAL participants
early release of chromogranin A (CgA) in patients with neuroendocrine tumours (NET) treated with peptide receptor radionuclide therapy (PRRT).
DIAGNOSTIC_TEST
Lead Sponsor
Military Institute od Medicine National Research Institute
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions